Skip to search formSkip to main contentSkip to account menu

D 617

Known as: D-617 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
AIMS To investigate the potential induction by rifampicin of intestinal CYP2C8, CYP2C9, CYP2D6 and CYP3A4 using preparations of… 
Highly Cited
2004
Highly Cited
2004
SummaryThe calcium channel blocker verapamil[2,8-bis-(3,4-dimethoxyphenyl)-6-methyl-2-isopropyl-6-azaoctanitrile] is widely used… 
Highly Cited
2004
Highly Cited
2004
The calcium channel blocker verapamil [2,8-bis-(3,4-dimethoxyphenyl)-6-methyl-2-isopropyl-6-azaoctanitrile] undergoes extensive… 
Highly Cited
2002
Highly Cited
2002
Dietary constituents (e.g., in grapefruit juice; NaCl) and phytochemicals (e.g., St. John's wort) are important agents modifying… 
Highly Cited
2001
Highly Cited
2001
P‐glycoprotein (P‐gp) can limit the intestinal permeability of a number of compounds and may therefore influence their exposure… 
Highly Cited
2000
Highly Cited
2000
Verapamil is subject to extensive oxidative metabolism mediated by cytochrome P450 enzymes with less than 5% of an oral dose… 
Highly Cited
1999
Highly Cited
1999
AIMS The present study was conducted to evaluate metabolism of the enantiomers of verapamil and norverapamil using a broad range… 
Highly Cited
1990
Highly Cited
1990
The pharmacokinetics, metabolism and pharmacodynamics of verapamil (160 mg p.o. of a pseudoracemic mixture) were evaluated in six…